# A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

> **NCT00788060** · PHASE1 · COMPLETED · sponsor: **Daniel George, MD** · enrollment: 5 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Everolimus (RAD001)
- **DRUG:** Sunitinib (Sutent)

## Key facts

- **NCT ID:** NCT00788060
- **Lead sponsor:** Daniel George, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2015-02-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00788060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00788060, "A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00788060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*